ARTL — Artelo Biosciences Balance Sheet
0.000.00%
- $3.41m
- $1.07m
Annual balance sheet for Artelo Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2.14 | 10.1 | 17.5 | 10.4 | 2.34 |
Prepaid Expenses | |||||
Total Current Assets | 2.34 | 10.3 | 18.3 | 11 | 2.56 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0 | 0.09 | 0.06 | 0.021 | 0.099 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 4.38 | 12.6 | 20.4 | 13 | 4.7 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.502 | 0.526 | 0.998 | 1.29 | 1.77 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.502 | 0.593 | 1.02 | 1.29 | 1.84 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 3.87 | 12 | 19.4 | 11.8 | 2.86 |
Total Liabilities & Shareholders' Equity | 4.38 | 12.6 | 20.4 | 13 | 4.7 |
Total Common Shares Outstanding |